Abstracts Archive - Page 2368 of 2607 - ACR Meeting Abstracts

Abstract Number: 958 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine Changes In Rituximab-Treated Rheumatoid Arthritis Patients
Tamarah D. de Jong¹, Saskia Vosslamber¹, Wilco de Jager², Hennie G. Raterman³, Alexandre E. Voskuyl⁴, Kyra A. Gelderman¹ and Cornelis L. Verweij⁵, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Although rituximab therapy is successful in the majority of rheumatoid arthritis (RA) patients, 30-40% of patients do not respond. The mechanism behind this is…
Abstract Number: 959 • 2013 ACR/ARHP Annual Meeting
Interleukin 10 Negatively Correlates With Glycoprotein VI-Related Platelet Activation In Rheumatoid Arthritis (RA): A Novel Potential Target Of Cardiovascular Morbidity In RA
Leann Bell¹, Anne M. Madigan¹, Paul A. MacMullan¹, Eimear Dunne², Paola M. Bagaglia¹, Laura J. Durcan¹, Dermot Kenny² and Geraldine M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland
Background/Purpose: Patients with rheumatoid arthritis (RA) die prematurely of cardiovascular disease (CVD). Platelet mediated thrombosis is a major cause of CVD. Platelets amplify inflammation in RA via the collagen receptor,…
Abstract Number: 960 • 2013 ACR/ARHP Annual Meeting
Self-Perceived Efficacy of a Workshop On Musculoskeletal Clinical Anatomy
Miguel A. Saavedra¹, José E. Navarro-Zarza², J. Alvarez-Nemegyei³, Juan J. Canoso⁴, Robert A. Kalish⁵, Pablo Villaseñor-Ovies⁶ and Cristina Hernández-Díaz⁷, ¹Rheumatology, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ²Mexican Taskforce for the Advancement of Clinical Anatomy, Mexico, Mexico, ³Instituto Mexicano del Seguro Social, Merida, Mexico, ⁴Medicine/Rheumatology, ABC Medical Center and Tufts University, Mexico City, Mexico, ⁵Div of Rheumatology, Tufts Medical Center, Boston, MA, ⁶Hospital Angeles Tijuana, Tijuana, Mexico, ⁷Musculoskeletal Ultrasound, Instituto Nacional de Rehabilitación, Mexico City, Mexico
Background/Purpose: Knowledge of musculoskeletal anatomy is suboptimal at many levels of rheumatology training and practice. In a recent practical anatomy pre-test administered prior to a…
Abstract Number: 961 • 2013 ACR/ARHP Annual Meeting
Assessment and Promotion of a National Immunology Curriculum for Adult Rheumatology Residents
Dharini Mahendira¹, Shirley L. Chow², Sari Herman-Kideckel³ and Heather McDonald-Blumer⁴, ¹Rheumatology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Allergy and Immunology, University of Toronto, North York, ON, Canada, ⁴Rheumatology, Division of Rheumatology, Mount Sinai Hospital; Osteoporosis Program, Toronto General Hospital, Toronto, ON, Canada
Background/Purpose: Immunologic mechanisms play an integral role in understanding the pathogenesis and management of rheumatic conditions. Currently, there is limited access to standardized formal instruction…
Abstract Number: 962 • 2013 ACR/ARHP Annual Meeting
Electronic Learning Module Enhances Rheumatology Education
Malini Juyal¹, Avis Ware¹, John Houk¹ and Rina Mina², ¹Immunology, Allergy and Rheumatology, University of Cincinnati, Cincinnati, OH, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Electronic-learning (e-learning) has recently increased in use. Blended learning combines e-learning with traditional training. At the University of Cincinnati Division of Rheumatology, only traditional…
Abstract Number: 963 • 2013 ACR/ARHP Annual Meeting
Impact Of a Nurse-Led Program On Comorbidity Management In Rheumatoid Arthritis (RA): Results Of a Prospective, Multicenter, Randomized, Controlled Trial
Martin Soubrier¹, Elodie Perrodeau², Melanie Gilson³, Alain G. Cantagrel⁴, Xavier le Loet⁵, René-Marc Flipo⁶, Sandrine Guis⁷, Gael Mouterde⁸, Liana E. Euller-Ziegler⁹, Thierry Schaeverbeke¹⁰, Bruno Fautrel¹¹, Alain Saraux¹², Isabelle Chary-Valckenaere¹³, Gérard Chales¹⁴, Emmanuelle Dernis¹⁵, Pascal Richette¹⁶, Xavier Mariette¹⁷, Francis Berenbaum¹⁸, Jean Sibilia¹⁹, Philippe Ravaud²⁰ and Maxime Dougados²¹, ¹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ²Epidemiologist, Paris, France, ³CH Grenoble Hopital Sud, Grenoble, France, ⁴Dept of Rheumatology, Hopital Purpan, Toulouse CEDEX 9, France, ⁵Rheumatology Department, CHU de ROUEN, Rouen, France, ⁶Hôpitaux Universitaires de Lille, France, France, ⁷Rheumatology1, CRMBM UMR CNRS 7339, Aix Marseille Univ; AP-HM, Marseille, France, ⁸Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, ⁹Service de Rhumatologie, L Archet Hospital (University), Nice CEDEX 3, France, ¹⁰Rhumatology departement, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹¹Rheumatology, UPMC - Paris 6 University, Paris, France, ¹²Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ¹³Rheumatology, Nancy Teaching Hospital, Nancy, France, ¹⁴CHU RENNES, Rennes, France, ¹⁵Centre Hospitalier, Le Mans, France, ¹⁶Centre Viggo Petersen / Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ¹⁷Paris-Sud University, Paris, France, ¹⁸Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ¹⁹Rheumatology, CHU Hautepierre, Strasbourg, France, ²⁰Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²¹Cochin Hospital, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of developing numerous comorbid conditions that affect both mortality and RA outcome. Objectives: To…
Abstract Number: 964 • 2013 ACR/ARHP Annual Meeting
Redesign Of a Rheumatology Curriculum For Internal Medicine Residents: Results Of Needs Assessment Survey
Susan F. Kroop¹, Cecilia P. Chung² and Charlene M. Dewey³, ¹Medicine/Rheumatology, Vanderbilt University Medical School, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Internal Medicine, Vanderbilt University School of Medicine, Nashville, TN
Background/Purpose: We plan to improve internal medicine (IM) resident competence in caring for patients with rheumatologic disease and increase resident interest in rheumatology as a…
Abstract Number: 965 • 2013 ACR/ARHP Annual Meeting
The “Mini-Residency” In Musculoskeletal Care: An Efficient and Effective Mixed Method Model For Continuing Professional Education
Michael J. Battistone¹, Andrea M. Barker², Marissa Grotzke³, J Peter Beck⁴, Robert Z. Tashjian⁵, Timothy A. Huhtala⁶, Grant W. Cannon¹ and Patrice Kennedy⁷, ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ³Division of Endocrinology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁵Division of Orthopaedics, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Division of General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁷500 Foothill Boulevard, Salt Lake City VA, Salt Lake City, UT
Background/Purpose: The societal burden of musculoskeletal (MSK) disease is amplified by the limited number of subspecialists. Developing knowledge and skills of primary providers is projected…
Abstract Number: 966 • 2013 ACR/ARHP Annual Meeting
Less Is More? A Targeted Intervention Results In Substantial Improvement In rheumatologists’ Ordering Of Anti Nuclear Antibodies (ANA) In Patients With Rheumatic Complaints
Nienke Lesuis¹, Ester Piek², Hatice Demirel¹, Ronald F. van Vollenhoven³ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Laboratory, Sint Maartenskliniek, Nijmegen, Netherlands, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden
Background/Purpose: Anti-Nuclear Antibodies (ANA) are found both in patients with (non-)rheumatic diseases and in healthy controls1. ANA testing is useful in the diagnostic process of…
Abstract Number: 967 • 2013 ACR/ARHP Annual Meeting
‘Bending’ Ethical Norms To Serve Patients’ Interests: Tensions In Medical Professionalism
C. Ronald MacKenzie¹, Inmaculada de Melo-Martin², Michele Meltzer³ and Elizabeth A. Kitsis⁴, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Weill Cornell Medical College, New York, NY, ³Rheumatology, Jefferson Universtiy, Philadelphia, PA, ⁴Epidemiology & Medicine, Albert Einstein College of Med, Bronx, NY
Background/Purpose: The rheumatic diseases are a common cause of short and long-term disability. Affecting all sectors of the population, they diminish wellbeing, affect quality of…
Abstract Number: 930 • 2013 ACR/ARHP Annual Meeting
The Endocannabinoid Anandamide Modulates Adhesion, Proliferation and The Production Of Inflammatory Mediators In Rheumatoid Arthritis Synovial Fibroblasts By Activating CB₁, TRPV1, TRPA1 and Non-Cannabinoid Receptor Targets
Torsten Lowin, Angelika Graeber and Rainer H. Straub, Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) secrete large amounts of IL-6, IL-8 and matrix metalloproteinases (MMPs) which are crucial for cartilage destruction. RASFs…
Abstract Number: 939 • 2013 ACR/ARHP Annual Meeting
Reduction Of Circulating Blood Neutrophils In Mice By Anti-IL-6R Alpha Monoclonal Antibody is Not Due To Apoptosis Or Blockade Of Neutrophil Differentiation
Ludmila Kelly, Vilma Decman and Dimitris Skokos, Research, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Blockade of IL-6/IL-6Rα signaling is associated with a reduction of circulating neutrophils in the blood of patients treated with anti-IL-6Rα mAb but the mechanism…
Abstract Number: 928 • 2013 ACR/ARHP Annual Meeting
The Bioenergetic Role of HIF-1 and HIF-2 During Angiogenesis of Human Microvascular Endothelial Cells
Martin Hahne¹, Cindy Strehl¹, Manuela Jakstadt¹, Paula Hoff¹, Timo Gaber¹, Gerd Burmester² and Frank Buttgereit³, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Hypoxia is a feature of inflamed tissues. The transcription factors Hypoxia inducible factor (HIF)-1 and (HIF)-2 regulate the cellular and metabolic responses to reduced…
Abstract Number: 929 • 2013 ACR/ARHP Annual Meeting
Blockade Of TNFα Produced By TSLP-Primed CD1c Myeloid Dendritic Cells Skews T Cell Response To Th2 Activity In Rheumatoid Arthritis Patients
F.M. Moret¹, T.R.D.J. Radstake², J.W.J. Bijlsma¹, F.P.J.G. Lafeber¹ and J.A.G. van Roon³, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Thymic stromal lymphopoietin (TSLP) is well known for its potent activation of myeloid dendritic cells (mDCs) to induce Th2-mediated immune responses. Additionally, TSLP and…
Abstract Number: 931 • 2013 ACR/ARHP Annual Meeting
Effect Of Neutralizing IL-17A and IL-17F Antibodies On Host Resistance To Acute Mycobacterium Tuberculosis Infection In Mice In Comparison With Neutralizing TNF-α Treatment
Michael Kammüller¹, Franco Di Padova², Christian Antoni³, Salah-Dine Chibout⁴, Timothy Wright⁵, Marie-Laure Bourigault⁶, Noria Segueni⁶, Stephanie Rose⁶, Bernhard Ryffel⁶ and Valerie Quesniaux⁶, ¹PCS - Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland, ²Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶UMR7355 CNRS and University of Orleans, Orleans, France
Background/Purpose: Antibodies targeting IL-17A or IL-17RA are in clinical trials for the treatment of several autoimmune diseases. However, these therapies, by blocking critical mediators of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].